Cardiovascular Risk Reduction and the Role of New Antidiabetic Pharmacotherapies

  • Cardiovascular Risk Reduction and the Role of New Antidiabetic Pharmacotherapies (Slides) (Recording)

    Michael Miedema, MD, MPH
    Research Cardiologist at the Minneapolis Heart Institute Foundation®
    Director, Preventive Cardiology, Minneapolis Heart Institute® at Abbott Northwestern Hospital

    Matthew Lillyblad, PharmD, BCPS, AQ-Cardiology
    PGY2 Cardiology Residency Program Director, Abbott Northwestern Hospital
    Pharmacy Coordinator for Cardiology and Critical Care, Abbott Northwestern Hospital

See All Grand Rounds Listings

Physician: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Allina Health and Minneapolis Heart Institute Foundation. Allina Health is accredited by the ACCME to provide continuing medical education for physicians. Allina Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse: This activity has been designed to meet the Minnesota Board of Nursing continuing education requirements for 1.2 hours of credit. However, the nurse is responsible for determining whether this activity meets the requirements for acceptable continuing education.

Planning Committee: Dr. JoEllyn Abraham, Dr. Alex Campbell, Dr. Kevin Harris, Rebecca Lindberg, Dr. Michael Miedema, Dr. Scott Sharkey, Eva Zewdie and Jolene Bell Makowesky have declared that they do not have any conflicts of interest associated with the planning of this activity. Dr. David Hurrell declares the following relationship – honoraria: Boston Scientific.